Guided by these <i>in silico</i> findings, <i>in vivo</i> experiments demonstrated that BFL and CBF reduced tumor burden and proliferation, as evidenced by hematoxylin and eosin staining and Ki-67 immunohistochemistry. This evidence concerns the gene MKI67 and neoplasm.